Turkmenistan Approves Use of Russia’s EpiVacCorona Vaccine

BUSINESS TURKMENISTAN
Turkmenistan Approves Use of Russia’s EpiVacCorona Vaccine
Turkmenistan became the first state after the manufacturing country - the Russian Federation, to officially register EpiVacCorona vaccine. (Photo: TASS)

Turkmenistan approved the use of Russia’s second COVID-19 vaccine, EpiVacCorona, developed by the State Research Center for Virology and Biotechnology Vector.

Center for Registration of Medicines and State Control under the Ministry of Healthcare and Medical Industry of Turkmenistan issued the corresponding registration certificate. The registration was preceded by an expert analysis of the pharmacological and pharmacopoeia committees of the Center, Orient news outlet reported on Friday.

The issuance of the registration certificate for the vaccine authorizes the purchase and use of the drug in Turkmenistan for the prevention of the viral infection.

EpiVacCorona was registered in Russia in October 2020 and passed post-registration clinical trials. Turkmenistan became the first state after the manufacturing country - the Russian Federation, to officially register this vaccine.

In January 18, the Ministry of Healthcare and Medical Industry of Turkmenistan registered the Sputnik V vaccine developed by Russia’s Gamaleya Research Center. It is a vector vaccine based on a safe adenovirus that is used as a container to deliver selected proteins of the coronavirus into the body.

Vector's "EpiVacCorona" vaccine is a peptide synthetic vaccine. A peptide synthetic vaccine mimics certain parts of the pathogen they are designed to protect from, compelling the human body to produce antigens capable of fighting the original virus. According to experts, the drug is characterized by a fairly high level of safety.

Currently, representatives of the Central Research Institute of Epidemiology of Rospotrebnadzor are in Ashgabat.

The large-scale production of the EpiVacCorona vaccine, according to Russian Prime Minister Mikhail Mishustin, will begin in February.